Quoin Pharmaceuticals (QNRX) announces FDA clearance to initiate a new additional Netherton Syndrome clinical study for QRX003. QRX003 is a topical lotion that contains a broad-spectrum serine protease inhibitor designed to target the kallikreins in the skin responsible for the excessive skin shedding associated with this disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin Pharmaceuticals announces interim data from Netherton Syndrome studies
- Quoin Pharmaceuticals files to sell 19.23M ordinary shares
- Quoin Pharmaceuticals Annual Meeting Approves Key Amendments
- Quoin Pharmaceuticals at Risk of Nasdaq Delisting Amidst Financial Challenges
- Quoin Pharmaceuticals reports Q3 EPS ($1.63), consensus (49c)